Latest Vaccines Update: Novavax Approval, AIM’s mRNA Shingles Shot, Cholera Breakthrough & More 🦠🌐💉
In this week’s edition of Vaccine Research Updates, we bring you the latest developments transforming global immunization, from regulatory breakthroughs to strategic legal wins. Here’s what’s making headlines:
🇺🇸 FDA approves Novavax’s COVID-19 vaccine for individuals aged 65+ and those 12+ with underlying conditions like asthma and diabetes. Unlike mRNA vaccines, this traditional protein-based shot offers an alternative for high-risk groups.
🌏 AIM Vaccine’s mRNA shingles vaccine becomes the first globally to gain clinical approval in both the U.S. and China. With China’s shingles vaccination rate below one percent, this move opens up a vast new market.
⚖️ SK bioscience wins a major legal battle against Pfizer, paving the way for global exports of its 13-valent pneumococcal vaccine and advancing its 21-valent candidate with Sanofi.
🌊 Bharat Biotech’s Hillchol oral cholera vaccine delivers strong Phase 3 results across all age groups. With a production capacity of 200 million doses, rollout is expected soon to meet the 100 million annual global demand.
⏳ Moderna delays approval of its flu/COVID combo vaccine to 2026, opting to include updated Phase 3 efficacy data. Results from a 40,000-subject trial are expected later this year.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine research
#VaccineResearch #Novavax #mRNAVaccine #CholeraVaccine #ShinglesVaccine #GlobalHealth #BharatBiotech #ModernaUpdate #PublicHealth #SKBioscience #PfizerLawsuit #PneumococcalVaccine #VaccineInnovation #ClinicalTrials #LucidQuest #InfectiousDisease #ImmunizationStrategy #BiotechNews #PandemicPreparedness #HealthcareConsulting